We recently found that a class of clinically approved anti-cancer compounds reversed memory loss and restored normal numbers of synapses and dendritic spines in mouse models of Alzheimer’s Disease (AD). These findings offer an exciting possibility these compounds could be used to reverse the symptoms of AD in AD patients. ...
September 24, 2024
Testing the amyloid hypothesis of Alzheimer’s disease in vivo By Sam Gandy In this issue of The Lancet Neurology, Rinne and colleagues1 report something of a breakthrough by demonstrating the feasibility of eventually testing the so-called amyloid hypothesis of sporadic Alzheimer’s disease in vivo. According to their analysis, a passive immunotherapy protocol ...
March 2, 2010
October 15, 2019
2023 Why does Alzheimer’s disease (AD) risk increase with aging? Current AD therapy focuses on the removal of senile plaque amyloid that contains fibrils aggregated from the small protein amyloid beta peptide. Our new data show that brain levels of the small, soluble amyloid peptide increase in mice during normal aging, two ...
February 11, 2022
***** On January 31, 2024, in a press release, Biogen announced that it is discontinuing production of Aduhelm. From the release, “The company will discontinue the development and commercialization of ADUHELM® (aducanumab-avwa) 100 mg/mL injection for intravenous use and will terminate the ENVISION clinical study.” ***** On April 7, 2022, the ...
May 3, 2022
November 5, 2021
Dr. Meytal Landau holds a B. Pharm from the Hebrew University of Jerusalem, a Ph.D. degree from Tel-Aviv University, and conducted her postdoctoral research at UCLA with Prof. David Eisenberg. Landau heads a research lab at the Technion – Israel Institute of Technology, and is establishing a new lab at ...
December 23, 2022
Cure Alzheimer’s Fund’s $100,000 grant to Rockefeller University’s Dr. Paul Greengard was featured in USA Today online “Charity in the News: Week in Review.” The Nobel Laureate will use the grant to continue his studies on identifying brains cells that are vulnerable to Alzheimer’s. His studies could lead to the ...
May 16, 2011
Meg Smith, Chief Executive Officer Dear Friends, As summer comes to a close, I am delighted to share an update on our progress and achievements dedicated to advancing research in understanding Alzheimer’s disease (AD). Your support and dedication are instrumental in driving our mission forward, and it is with great pride that ...
September 6, 2024
2019 Neuritic plaques surround amyloid deposits and are made up of swollen, dystrophic neural processes that contain aggregated phosphorylated tau. Neurofibrillary tangles are made up of phosphorylated tau that has abnormally been aggregated in Alzheimer’s disease. Tau normally is microtubule adaptor protein involved in the highways of neurons that allow for ...
January 11, 2016
